Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Stock Information for Arbutus Biopharma Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Arbutus Biopharma Corporation

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
Arbutus to Participate in Two Upcoming Investor Conferences
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.